Recent advances in analytical chemistry have led to the emergence of a new field called metabolomics. Metabolomics allows the simultaneous measurement of 100’s to 1000’s of metabolites for mapping perturbations in interconnected pathways and networks, enabling a systems approach to the study of disease.
A partnership has been initiated between the metabolomics community and the Alzheimer’s Disease (AD) community through the ADNI (Alzheimer’s Disease Neuroimaging Initiative) consortium. We have already mapped several metabolic defects in AD (see ADMC Publications page) and are replicating and expanding findings using ADNI samples. We are also working to build a metabolomics database for ADNI, which will become a resource for the global Alzheimer’s research community.